Piper Sandler raised the firm’s price target on 10x Genomics (TXG) to $19 from $15 and keeps a Neutral rating on the shares. The firm cites the company’s quarterly results for the price target change.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- 10X Genomics Earnings Call: Mixed Results Amid Challenges
- Cathie Wood Buys the Dip in Archer Aviation (ACHR) After Weak Q3 Results, Trims Stakes in Roku and TER Stocks
- 10x Genomics: Balancing Growth Potential with Macroeconomic Challenges – Hold Rating Maintained
- 10x Genomics price target raised to $14 from $13 at UBS
- 10x Genomics price target raised to $15 from $13 at JPMorgan